

FFW



I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:
 Commissioner for Patents, P.O. Box 1450, Alexandria,
 Virginia 22313-1450, on June 29, 2004.
Michael L. Culotta
 Name
Michael L. Culotta
 Signature
June 29, 2004
 Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Peter Rohnert
 Filed: January 26, 2004
 Serial No.: 10/764,676
 For: Drug Preparation Comprising Alpha-Lipoic Acid, Ambroxol And/Or Inhibitors Of The Angiotensin-Converting Enzyme (ACE) And Its Use For The Treatment Of Neurodegenerative Diseases

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

Sir:

Applicant wishes to make of record the following references under the provisions of 37 C.F.R. §1.97 (legible copies of the references are enclosed).

US 2002/0177558 A1	Kozhevnikova et al.
WO 02/096398 A2	Packer et al.
WO 02/096414 A1	Ravati et al.
European Search Report	Stoll et al.
corresponding to 04001224.7-2107	
Jablonka et al.	Werner et al.


Please see attached form PTO/SB/08A for a listing of the references.

It is believed no fee is due with this *Information Disclosure Statement*. If a fee is due, please charge deposit account number 08-2442.

The person making this statement is the patent attorney who signs below on the basis of the information supplied by the inventor, and as the attorney associated with the filing and prosecution of this application (37 CFR 1.56(a)).

Respectfully submitted,

By:


 John D. Lopinski, Reg. No. 50,846

HODGSON RUSS LLP
 One M & T Plaza, Suite 2000
 Buffalo, New York 14203-2391
 Date: June 29, 2004

Please type a plus sign inside this box +


PTO/SB/08A(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 2

Application Number	10/764,676
Filing Date	January 26, 2004
First Named Inventor	Peter Rohnert
Art Unit	1615
Examiner Name	
Attorney Docket Number	13183.0037



Sheet 1 of 2

Attorney Docket Number 13183.0037

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
		WO 02/096398 A2	12-05-2002	Esparma GmbH et al.	
		WO 02/096414 A1	12-05-2002	Serumwerk Bernburg AG	

**Examiner
Signature** **Date
Considered**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/764,676
Filing Date	January 26, 2004
First Named Inventor	Peter Rohner
Group Art Unit	1615
Examiner Name	

Attorney Docket Number 13183.0037

JUL 02 2004

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		European Search Report corresponding to 04001224.7-2107.	
		JABLONKA, STANISLAW, ANDRZEJ LEDWOZYW, WOJCIECH KADZIOLKA, ANDRZEJ JABLONKA, AND ANDRZEJ NESTOROWICZ, "The Influence Of Ambroxol On Peroxidative Processes In Lung And Plasma In Dogs After Pulmonectomy," <u>Archivum Veterinarium Polonicum</u> , 1992, Pages 57-66, Volume 32, Number 1-2.	
		KOZHEVNIKOVA, E.V. AND L.M. ADZHIENKO, "Neuroprotective Activity Of Angiotensin-Converting Enzyme Inhibitors In Cerebral Ischemia," <u>Bulletin Of Experimental Biology And Medicine</u> , 1999, Pages 1122-1124, Volume 11.	
		PACKER, LESTER, HANS J. TRITSCHLER, AND KLAUS WESSEL, "Neuroprotection By The Metabolic Antioxidant α -Lipoic Acid," <u>Free Radical Biology & Medicine</u> , 1997, Pages 359-378, Volume 22, Numbers 1/2.	
		RAVATI, ALEXANDER, VERA JUNKER, MARIA KOUKLEI, BARBARA AHLEMAYER, CARSTEN CULMSEE, AND JOSEF KRIEGLSTEIN, "Enalapril And Moexipril Protect From Free Radical-Induced Neuronal Damage In Vitro And Reduce Ischemic Brain Injury In Mice And Rats," <u>European Journal Of Pharmacology</u> , 1999, Pages 21-33, Volume 373.	
		STOLL, S., A. ROSTOCK, R. BARTSCH, E. KORN, A. MEICHELBOCK, AND W.E. MÜLLER, "The Potent Free Radical Scavenger α -Lipoic Acid Improves Cognition In Rodents," <u>Annals New York Academy Of Sciences</u> , 1994, Pages 122-128.	
		WERNER, CHRISTIAN, WILLIAM E. HOFFMAN, EBERHARD KOCHS, SARA F. RABITO, AND DAVID J. MILETICH, "Captopril Improves Neurologic Outcome From Incomplete Cerebral Ischemia In Rats," <u>Stroke</u> , July 1991, Pages 910-914, Volume 22, Number 7.	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

BFLODOCS: 939527 v1 (K4XZ01!.DOC)